The Follicle Is Not a
Battlefield but a False Alarm For generations, the working picture of a pimple was simple and wrong. Bacteria invade, the body fights, pus forms. That model cannot survive a single observation: the bacterium at the center of acne, Cutibacterium acnes, lives on virtually every human face, including the faces of people who never develop a single lesion. If the germ were the cause, everyone would break out. The germ is a resident, not an intruder.
Richard Gallo at the University of California, San Diego states the correction plainly: acne is not an infection, it is an immune problem. [3] The skin is not losing a fight against a pathogen. It is overreacting to proteins the bacterium sheds in the ordinary course of its life. The immune system reads a routine signal as an emergency and answers with full force.
What that answer looks like at the cellular level is stranger than the old pus-and-bacteria story. In work published in Science Translational Medicine, Gallo’s team performed single-cell RNA sequencing on human acne lesions and on mouse skin exposed to C. acnes. [1] A specific subset of fibroblasts — the cells that build the skin’s structural scaffold — had switched on a program for becoming fat cells. This is reactive adipogenesis, and it is a normal defense against deep tissue infection, first mapped in Staphylococcus aureus infections. In acne, the same machinery fires when it should not.
The trigger is a toxin. C. acnes secretes a protein called Christie-Atkins-Munch-Petersen factor, or CAMP. The preadipocytes that turn fatty begin to produce cathelicidin, an antimicrobial peptide encoded by the CAMP gene. The sequence depends on TLR2, a receptor that recognizes bacterial components. In mice lacking the CAMP gene, retinoid treatment could no longer shrink acne-like lesions, even though the drug still blocked fat-cell conversion. A pimple, on this reading, is a follicle that mistook a houseguest for a burglar and pulled the fire alarm.
A Toxin, a Sugar-Cutting Enzyme, and Two Ways to Intercept Them
If the alarm is a protein, the alarm can be muted before it sounds. Gallo’s group tested the idea directly: vaccinate mice against CAMP so the animals produce antibodies that neutralize the toxin. Studies from the team suggest this approach could help prevent or treat acne. The pharmaceutical giant Sanofi has developed an mRNA vaccine targeting CAMP, possibly alongside other C. acnes proteins. As of the latest registry update on 18 September, the trial is listed as “not yet recruiting,” despite earlier reports that it had begun.
The trial design carries an unusual feature. A conventional vaccine trial waits months or years for volunteers to meet a pathogen. Here the outcome is visible on the skin, so volunteers could know within weeks whether their acne is changing. Initial trials are built to establish safety first. Gallo’s own words carry both the hope and the caution: “We were very, very optimistic that this could be revolutionary for acne therapy. We’ll just have to see if it pans out in the human population.” [3]
A second company is aiming at a different protein. George Liu at the University of California, San Diego studied hyaluronidase, an enzyme that breaks down hyaluronic acid — a large sugar secreted into the spaces between cells. The same pair of molecules appears in cosmetic medicine, where hyaluronic acid fills wrinkles and hyaluronidase dissolves unwanted filler. Liu’s team found that hyaluronidase comes in two functional types. One chops hyaluronic acid into simple sugars. The other leaves large fragments, and those fragments act as an alarm signal to the immune system. Searching genetic databases for which bacteria carry which type, the researchers found the simple-sugar version was the most common. The alarm-fragment version was confined to a handful of free-living bacteria — organisms with no immune system to worry about.
C. acnes was the exception. Some strains produce the simple-sugar enzyme, others the alarm-fragment enzyme. No strain produces both. In mouse studies, alarm-fragment strains drove acne-related inflammation; simple-sugar strains slightly reduced it. A vaccine that raises antibodies against only the alarm-fragment form reduced acne in mice, as did a small protein that inhibited the enzyme. Armora Biosciences, the start-up founded around this work, is pursuing that target. Tomasz Zastawny at Armora frames the stakes in human terms: “Acne causes a significant emotional burden. It can lead to the development of depression, social isolation and other psychological outcomes as well.” [3]
A Vaccine That Cannot Be Outrun by Resistance
The two approaches converge on a single structural advantage, and it is worth pausing on why. Antibiotics, the standard prescription for moderate to severe acne, kill helpful C. acnes strains alongside harmful ones. That collateral damage may explain part of their limited effectiveness. Resistance, the perennial companion of antibiotics, adds a second problem. Isotretinoin, sold as Roaccutane, works better than antibiotics but carries a long list of side effects including birth defects, impotence, and dry, itchy skin, and its mechanism remains unclear.
Vaccines sidestep both traps because they do not target the bacterium. They target proteins the bacterium secretes. Lasting side effects are not expected, and resistance is unlikely because the vaccines target secreted proteins rather than the bacteria themselves.
The deepest open question is evolutionary, and it belongs to microbiology as much as to dermatology. Why would some strains of C. acnes have evolved a hyaluronidase that deliberately provokes the immune system? Liu’s hypothesis is competition — the alarm may be a weapon against rival bacteria sharing the follicle. If that is right, the inflammatory strain is not malfunctioning. It is playing a game whose rules predate human skin. A vaccine would intervene in an ecology we are only beginning to read, and the next question — whether removing the alarm-fragment strains reshapes the follicle’s bacterial community — is one no current trial is designed to answer.
For people with severe, inflamed acne, the practical picture is narrower. Liu expects a vaccine against the alarm-fragment enzyme to work best on “the more severe, red, angry type of acne lesion” — “the ones that are hard to treat right now.” If one vaccine fails, the other may not. If both work, the combination might outperform either alone. Adolescence, just maybe, is about to get a little easier.
Sources
- DOI: 10.1126/scitranslmed.abh1478
- DOI: 10.1016/j.jid.2018.05.032
- Newscientist — Quote source (original article)